Log in

NASDAQ:NBRV - Nabriva Therapeutics Stock Price, Forecast & News

$0.57
-0.02 (-3.36 %)
(As of 04/1/2020 03:25 AM ET)
Today's Range
$0.56
Now: $0.58
$0.62
50-Day Range
$0.50
MA: $1.15
$1.59
52-Week Range
$0.50
Now: $0.58
$3.19
Volume1.08 million shs
Average Volume1.50 million shs
Market Capitalization$544.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Read More
Nabriva Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NBRV
CUSIPN/A
Phone353-1649-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.48 million
Book Value$0.04 per share

Profitability

Net Income$-82,760,000.00
Net Margins-872.95%

Miscellaneous

EmployeesN/A
Market Cap$544.08 million
Next Earnings Date5/8/2020 (Estimated)
OptionableOptionable

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.


Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

How has Nabriva Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NBRV shares have decreased by 52.5% and is now trading at $0.5750. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nabriva Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nabriva Therapeutics.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Nabriva Therapeutics.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics PLC - (NASDAQ:NBRV) posted its quarterly earnings data on Thursday, March, 12th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The biotechnology company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $1.60 million. Nabriva Therapeutics had a negative net margin of 872.95% and a negative return on equity of 179.92%. View Nabriva Therapeutics' earnings history.

What price target have analysts set for NBRV?

7 equities research analysts have issued 12 month price objectives for Nabriva Therapeutics' shares. Their forecasts range from $1.00 to $13.00. On average, they anticipate Nabriva Therapeutics' stock price to reach $5.14 in the next year. This suggests a possible upside of 794.4% from the stock's current price. View analysts' price targets for Nabriva Therapeutics.

Has Nabriva Therapeutics been receiving favorable news coverage?

Press coverage about NBRV stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View the latest news aboutNabriva Therapeutics.

Who are some of Nabriva Therapeutics' key competitors?

What other stocks do shareholders of Nabriva Therapeutics own?

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the following people:
  • Mr. Steven P. Gelone, Pres & COO (Age 51)
  • Dr. Colin Broom, Consultant & Director (Age 63)
  • Mr. Gary L. Sender, Chief Financial Officer (Age 57)
  • Mr. Theodore R. Schroeder, CEO & Director (Age 64)
  • Mr. Thomas Lembck, Chief Information Officer

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $0.58.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $544.08 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.  View additional information about Nabriva Therapeutics.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is http://www.nabriva.com/.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]


MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel